William Dall’Acqua is Senior Director Research & Development at MedImmune, Gaithersburg, where he supervises a group in the Department of Antibody Discovery and Protein Engineering.

His team of 29 scientists is working on the discovery of new therapeutic antibody drugs and establishing novel antibody technology platforms. In particular, William’s group has developed a novel and groundbreaking strategy to improve the serum half-life of human IgG. Such long-lasting molecules have the potential to make an impact in the field of antibody-based therapy.

William has been studying protein structure, function and engineering for over 20 years and has co-authored over 45 papers and one book chapter in the field. He has also been named inventor on 16 issued patents. He has Bachelor and Masters’ Degrees in Biochemistry from University of Paris, and a Ph.D. in Immunology from University of Paris in conjunction with University of Maryland. He also spent two and a half years as a post-doctoral fellow at Genentech’s Molecular Oncology Department, before joining MedImmune.


The YTE leap in technology



LATREST PROJECT

The YTE leap in technology

Position

Antibody Lead Generation, Gaithersburg

Peer recognition

Elsevier publication co-editor, peer publication reviewer, NIH site reviewer, panelist, SAB member and speaker at multiple conferencesNovel Antibodies For Brain Tumor Therapy


Featured Publications

Enhancement of antibody-dependent cell-mediated cytotoxicity

Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding. Borrok MJ, Luheshi NM, Beyaz N, Davies GC, Legg JW, Wu H, Dall'Acqua WF, Tsui P. MAbs. 2015 4; 7(4):743-51.

Structural Insights into Sifalimumab

Structural Insights into the Neutralization Properties of the Fully Human, Anti-interferon Monoclonal Antibody Sifalimumab. Oganesyan V, Peng L, Woods RM, Wu H, Dall'Acqua WF. J Biol Chem. 2015; 290(24):14979-85.

Molecular basis of bispecific antibody's target selectivity

Insights into the molecular basis of a bispecific antibody's target selectivity. Mazor Y, Hansen A, Yang C, Chowdhury PS, Wang J, Stephens G, Wu H, Dall'Acqua WF. MAbs. 2015; 7(3):461-9.
doi: 10.1080/19420862.2015.1022695.

Improving target cell specificity

Improving target cell specificity using a novel monovalent bispecific IgG design. Mazor Y, Oganesyan V, Yang C, Hansen A, Wang J, Liu H, Sachsenmeier K, Carlson M, Gadre DV, Borrok MJ, Yu XQ, Dall'Acqua W, Wu H, Chowdhury PS. MAbs. 2015; 7(2):377-89. doi: 10.1080/19420862.2015.1007816.

Antagonistic activity of anifrolumab

Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-α receptor 1 antibody. Peng L, Oganesyan V, Wu H, Dall'Acqua WF, Damschroder MM. MAbs. 2015; 7(2):428-39.

FcRn affinity threshold that governs IgG recycling

pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling. Borrok MJ, Wu Y, Beyaz N, Yu XQ, Oganesyan V, Dall'Acqua WF, Tsui P. J Biol Chem. 2015 ; 290(7):4282-90.



It is an amazing feeling to see something you've worked on in the lab make it to patients and make a difference.

William Dall’Acqua Senior Director, R&D, Antibody Discovery and Protein Engineering

Join us at MedImmune

Our Great Place to Work strategic initiative offers a dynamic environment that fosters collaboration and innovation. We attract top minds, and we do what it takes to nurture and build talent.